Justices Won't Review Class Cert. In Diabetes Drug Risk Case
By Mark Payne · March 24, 2026, 1:23 PM EDT
The U.S. Supreme Court has declined to review whether a federal court can certify a class of third-party payors who claim drugmakers hid the cancer risks of an anti-diabetes drug....
To view the full article, register now.